Dear Editor,

The current pandemic on Coronavirus disease 19 (COVID-19) is a matter of serious concern to all doctors. Since many patients with rheumatic diseases are on immunosuppressive therapies, they constitute a potentially vulnerable population for this devastating disease. In this study, we have conducted a survey amongst rheumatologists in India to gather their perspectives on the changes in management of rheumatic illnesses in the times of COVID-19 pandemic.Such findings may help influence practice and provide ideas for further exploration of the influence of COVID-19 on the management of patients with rheumatic diseases.

We sincerely hope this would be of interest to the readers of your esteemed journal.

Regards,

LG, DPM, VA, SB, VA

**Management of rheumatic diseases in the times of COVID-19 pandemic- perspectives of rheumatology practitioners from India**

**Author’s name:**

**Latika Gupta1**

**Durga Prasanna Misra1**

**Vishwesh Agarwal 2**

**Suma Balan 3**

**Vikas Agarwal1**

**Name of the Department and Institution:**

1Department of Clinical Immunology and Rheumatology

Sanjay Gandhi Postgraduate Institute of Medical Sciences

Lucknow, India

2 Mahatma Gandhi Medical College,

Navi Mumbai, India

3 Department of Paediatric Rheumatology,

Amrita Institute of Medical Sciences, Kochi

**Correspondence to:**

Prof Vikas Agarwal

Professor

Department of Clinical Immunology and Rheumatology

Sanjay Gandhi Postgraduate Institute of Medical Sciences

Lucknow, India, 226014

vikasagr@yahoo.com

+91-522-2494183

**Abstract.**

**Objective.**

The Coronavirus disease 19 (COVID-19) pandemic has led to widespread concerns about the risk of infection in patients with rheumatic diseases (RD) receiving disease modifying ant-rheumatic drugs (DMARDs) and other immunosuppressants (IS).

**Methods.**

A SurveyMonkey® based electronic survey was conducted amongst members of the Indian Rheumatology Association to understand the need for changes in prevailing practices.

**Results.**

Of the 861 invitees, 221 responded. In the wake of the pandemic, 47.5% would reduce biological DMARDs (bDMARDs) while only 12.2% would reduce the use of conventional synthetic DMARDs. 64.2% were likely to defer change in IS, the reluctance being most with rituximab (58.3%) followed by cyclophosphamide (53.3%), anti-tumor necrosis factor alpha agents (52.4%) and Janus kinase inhibitors (34.39%).

Hydroxychloroquine was the preferred choice (81.9%) for the treatment of COVID-19 followed by protease inhibitors (22.1%) and intravenous immunoglobulin (8.1%). Chloroquine was less preferred (19%). More than two-thirds (70.5%) believed that  COVID-19 might trigger macrophage activation syndrome. Social distancing (98.1%) and hand hygiene (74.6%) were recommended by majority. 62.8% would avoid touch for clinical examination whenever feasible.

**Conclusion.**

Most rheumatologists perceived the need to change treatment of RDs during the COVID-19 pandemic; reduce immunosuppression and defer the usage of rituximab and bDMARDs.

**Running Title:**Rheumatology practice during COVID-19

**Competing interests:**The authors declare that there is no conflict of interest

**Contributorship:**  All authors were involved in ideation, data collection and manuscript preparation. All authors agree with the submitted version of the manuscript, take responsibility for the content of the entire manuscript, and affirm that any queries related to any aspect of the same are appropriately managed.

**Acknowledgements:**None

**Funding statement:**This study was not funded.

**Ethical approval information:** Exemption from review was obtained from the institute ethics committee (2018-62-IP-EXP) of SGPGIMS, Lucknow as per local guidelines
**Data sharing statement:**All data pertaining to the study is included in themanuscript and as supplementary material.
**Patient and Public Involvement:**The surveywas completely anonymised and informed consent taken from the respondents at the beginning of the exercise.

**Key messages**

**What is already known about this subject?**

Patients with rheumatic diseases receiving glucocorticoids, disease modifying ant-rheumatic drugs and other immunosuppressants  have increased susceptibility to infections including respiratory tract infections

**What does this study add?**

o   There is an urgent need to revise the management of rheumatic diseases as perceived by a large group of practicing rheumatologists in India in the times of the COVID-19 pandemic.

o   There is reluctance to initiate biological DMARDs (especially Rituximab and anti-TNF agents), tsDMARDs (JAK inhibitors) and cyclophosphamide.

o     There is an inclination to prescribe hydroxychloroquine (HCQ) even for rheumatic diseases with weak level of evidence.

 **How might this impact on clinical practice?**

This might identify areas to be addressed in a Delphi exercise to develop expert evidence to guide the management of RDs during the pandemic.